Avaneesh Kumar Pandey, Nusrat Shafiq, Ashish Kumar Kakkar, Samir Malhotra, Beth Woods, Christopher Little, Tom Rhodes, Harriet Tuson, Zeshan Riaz, Tom Ashfield, Michael Corley, Ioannis Baltas
{"title":"抗菌药物定价。","authors":"Avaneesh Kumar Pandey, Nusrat Shafiq, Ashish Kumar Kakkar, Samir Malhotra, Beth Woods, Christopher Little, Tom Rhodes, Harriet Tuson, Zeshan Riaz, Tom Ashfield, Michael Corley, Ioannis Baltas","doi":"10.1038/s43856-024-00594-9","DOIUrl":null,"url":null,"abstract":"Despite the constant development of antimicrobial resistance (AMR), few new antimicrobials are currently becoming available clinically. Alternative approaches, such as different mechanisms to fund their use, are being explored to encourage development of new antimicrobials.","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":null,"pages":null},"PeriodicalIF":5.4000,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s43856-024-00594-9.pdf","citationCount":"0","resultStr":"{\"title\":\"Antimicrobial drug pricing\",\"authors\":\"Avaneesh Kumar Pandey, Nusrat Shafiq, Ashish Kumar Kakkar, Samir Malhotra, Beth Woods, Christopher Little, Tom Rhodes, Harriet Tuson, Zeshan Riaz, Tom Ashfield, Michael Corley, Ioannis Baltas\",\"doi\":\"10.1038/s43856-024-00594-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Despite the constant development of antimicrobial resistance (AMR), few new antimicrobials are currently becoming available clinically. Alternative approaches, such as different mechanisms to fund their use, are being explored to encourage development of new antimicrobials.\",\"PeriodicalId\":72646,\"journal\":{\"name\":\"Communications medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.4000,\"publicationDate\":\"2024-10-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.nature.com/articles/s43856-024-00594-9.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Communications medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.nature.com/articles/s43856-024-00594-9\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Communications medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.nature.com/articles/s43856-024-00594-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Despite the constant development of antimicrobial resistance (AMR), few new antimicrobials are currently becoming available clinically. Alternative approaches, such as different mechanisms to fund their use, are being explored to encourage development of new antimicrobials.